Thymosin fraction-5 possesses antiproliferative properties in HL-60 human promyelocytic leukemia cells: characterization of an active peptide.
Thymosin fraction-5 (TF5) is a protein preparation of the bovine thymus. TF5 stimulates many assays of T cell-mediated immunity. We found that TF5 substantially suppressed proliferation of the rat C6 glioma and MMQ pituitary adenoma cell lines. Our current research using the promyelocytic cell line HL-60 suggests that TF5 also prevents proliferation of human myeloid leukemia cells. Our objective is the purification and chemical characterization of TF5 peptide components responsible for inhibition of HL-60 proliferative capacity. Using the inhibition of HL-60 cell proliferation, we have chemically characterized TF5 using fast protein liquid chromatography (FPLC), reversed-phase high-performance liquid chromatography (RP-HPLC), and high-performance capillary electrophoresis (HPCE). Vital dye-exclusion, oxidative metabolism of chromogenic dyes, and clonogenic growth profiles were used to determine rates of HL-60 proliferation. Our results identified an approximately 6000 Da component of TF5 capable of inducing HL-60 growth arrest. Synchronized HL-60 cells exposed to TF5 and its various constituents were subjected to cytometric analysis by flow cytometry. TF5-treated HL-60 cells had an increased subdiploid faction (i.e., sub-G1) compared to control cells. TF5 also increased Annexin V staining in randomly cycling HL-60 cells. Thus, a TF5 subfraction possesses growth-suppressive activity for human myeloid neoplasms. Our results indicate that this effect is characterized by at least one hallmark of apoptosis. Future clinical management strategies for certain leukemias may involve the use of thymic peptides.
Spangelo
Bryan L
BL
Department of Chemistry, University of Nevada Las Vegas, 4505 Maryland Parkway, Las Vegas, NV 89154-4003, USA. bryan.spangelo@unlv.edu
Roach
Joseph D
JD
Hadi
Freidun
F
Damavandy
Ali A
AA
Plieskatt
Jordan
J
Badamchian
Mahnaz
M
D000595:Amino Acid Sequence; D000818:Animals; D016588:Anticarcinogenic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D002417:Cattle; D002455:Cell Division / Q000187:drug effects*; D045744:Cell Line, Tumor; D005910:Glioma; D018922:HL-60 Cells / Q000166:cytology* / Q000187:drug effects; D006801:Humans; D008969:Molecular Sequence Data; D009218:Myosins; D010446:Peptide Fragments / Q000494:pharmacology; D010911:Pituitary Neoplasms; D013947:Thymosin / Q000031:analogs & derivatives* / Q000737:chemistry / Q000302:isolation & purification / Q000494:pharmacology; D013950:Thymus Gland; D000099201:Thymosin beta(4)
D016588:Anticarcinogenic Agents; D009218:Myosins; D010446:Peptide Fragments; D013947:Thymosin; D000099201:Thymosin beta(4); C033782:thymosin fraction 5